COSCIENS Biopharma Inc. (CSCI)

NASDAQ: CSCI · Real-Time Price · USD
3.000
-0.300 (-9.09%)
Nov 12, 2024, 4:00 PM EST - Market closed
-9.09%
Market Cap 12.62M
Revenue (ttm) 4.92M
Net Income (ttm) -18.23M
Shares Out 3.70M
EPS (ttm) -13.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,564
Open 3.250
Previous Close 3.300
Day's Range 2.810 - 3.250
52-Week Range 2.810 - 11.100
Beta 2.27
Analysts n/a
Price Target n/a
Earnings Date Nov 12, 2024

About CSCI

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocr... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 18, 1996
Employees 12
Stock Exchange NASDAQ
Ticker Symbol CSCI
Full Company Profile

Financial Performance

In 2023, COSCIENS Biopharma's revenue was $4.50 million, a decrease of -20.25% compared to the previous year's $5.64 million. Losses were -$16.55 million, -27.17% less than in 2022.

Financial numbers in USD Financial Statements

News

COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs

Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- C...

9 hours ago - GlobeNewsWire

COSCIENS Biopharma Announces Change to Board of Directors

TORONTO, ONTARIO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializi...

5 weeks ago - GlobeNewsWire

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializi...

6 weeks ago - GlobeNewsWire

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs

TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializ...

7 weeks ago - GlobeNewsWire

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of mac...

2 months ago - GlobeNewsWire

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024

3 months ago - GlobeNewsWire